1. Home
  2. ZLAB vs WGS Comparison

ZLAB vs WGS Comparison

Compare ZLAB & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zai Lab Limited

ZLAB

Zai Lab Limited

HOLD

Current Price

$26.25

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

HOLD

Current Price

$83.32

Market Cap

2.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZLAB
WGS
Founded
2013
2017
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.7B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
ZLAB
WGS
Price
$26.25
$83.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
7
Target Price
$49.60
$120.71
AVG Volume (30 Days)
1.2M
455.5K
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
38.46
62.37
EPS
N/A
N/A
Revenue
$460,156,000.00
$427,539,000.00
Revenue This Year
$9.75
$29.98
Revenue Next Year
$26.03
$25.92
P/E Ratio
N/A
N/A
Revenue Growth
15.33
39.97
52 Week Low
$15.96
$32.21
52 Week High
$34.72
$170.87

Technical Indicators

Market Signals
Indicator
ZLAB
WGS
Relative Strength Index (RSI) 60.90 58.15
Support Level $16.98 $81.37
Resistance Level $27.08 $94.82
Average True Range (ATR) 0.84 3.95
MACD -0.19 -0.65
Stochastic Oscillator 53.72 48.70

Price Performance

Historical Comparison
ZLAB
WGS

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: